Literature DB >> 3910609

Comparative cytotoxicity between cisplatin and second generation platinum analogs.

B Drewinko, L Y Yang, J M Trujillo.   

Abstract

The cytotoxic activity of cis-DDP and four second generation platinum coordination complexes (TNO-6; JM-82; JM-8; and JM-9) was compared on six established human colon carcinoma cell lines with different degrees of differentiation. Cytotoxicity was evaluated by the inhibition of colony formation technique. Cis-DDP was uniformily active against all lines. JM-8 and JM-9 were virtually ineffective for all cell lines, even at concentrations as high as 50 micrograms/ml. JM-82 was slightly more active although (with the exception of LoVo cells) still about 10-fold less efficacious than cis-DDP. TNO-6 was the only derivative with appreciable cytotoxic activity although about 2 to 5-fold less than cis-DDP for lines SW48, 620, 480, and 1116. For LoVo and SW403, TNO-6 was slightly more active than cis-DDP. In both such instances, increased efficacy resulted from abrogation of the shoulder region of the survival curve while the slope remained essentially intact. Thus any enhancement in therapeutic efficacy with these second generation analogues can only be expected from possible decreases in toxic effects but not from superior tumor cell kill activity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3910609     DOI: 10.1007/bf00170755

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  14 in total

1.  A comparison of the lethal effects of three nitrosourea derivatives on cultured human lymphoma cells.

Authors:  B Drewinko; T L Loo; J A Gottlieb
Journal:  Cancer Res       Date:  1976-02       Impact factor: 12.701

2.  Comparison of in vitro methods to determine drug-induced cell lethality.

Authors:  P R Roper; B Drewinko
Journal:  Cancer Res       Date:  1976-07       Impact factor: 12.701

3.  Antitumor activity and toxicity of cisplatin analogs.

Authors:  W C Rose; J E Schurig; J B Huftalen; W T Bradner
Journal:  Cancer Treat Rep       Date:  1982-01

4.  Patterns of cell survival following treatment with antitumor agents in vitro.

Authors:  B Drewinko; P R Roper; B Barlogie
Journal:  Eur J Cancer       Date:  1979-01       Impact factor: 9.162

5.  In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C.

Authors:  B Barlogie; P M Corry; B Drewinko
Journal:  Cancer Res       Date:  1980-04       Impact factor: 12.701

6.  Anticancer activity of cis-dichlorodiammineplatinum(II) and some relevant chemistry.

Authors:  B Rosenberg
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

7.  Rationale for development of platinum analogs.

Authors:  J H Burchenal; K Kalaher; K Dew; L Lokys
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

8.  Antitumor activity, induction of cross-resistance, and nephrotoxicity of a new platinum analogue, cis-1,1-diaminomethylcyclohexaneplatinum(II) sulfate, and of cis-diamminedichloroplatinum(II) in an immunocytoma model in the LOU/M rat.

Authors:  W H de Jong; P A Steerenberg; J G Vos; E J Bulten; F Verbeek; W Kruizinga; E J Ruitenberg
Journal:  Cancer Res       Date:  1983-10       Impact factor: 12.701

9.  Synthesis and antitumor activity of new platinum complexes.

Authors:  D B Brown; A R Khokhar; M P Hacker; L Lokys; J H Burchenal; R A Newman; J J McCormack; D Frost
Journal:  J Med Chem       Date:  1982-08       Impact factor: 7.446

10.  Phase I clinical trial and pharmacokinetics of 4'-carboxyphthalato(1,2-diaminocyclohexane)platinum(II).

Authors:  D P Kelsen; H Scher; N Alcock; B Leyland-Jones; A Donner; L Williams; G Greene; J H Burchenal; C Tan; F S Philips; C W Young
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

View more
  1 in total

1.  Absolute and relative activities of platinum-complexes on human tumors as evaluated by an antimetabolic in vitro assay.

Authors:  M G Daidone; R Silvestrini; N Zaffaroni; E Grignolio; F Landoni
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.